Benzyl Phenethylcarbamate

Benzyl Phenethylcarbamate

SCHEMBL4287199

O=C(NCCc1ccccc1)OCc1ccccc1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
HTT P42858 1/20 0.69
TGM2 P21980 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.58
KEAP1 Q14145 2/20 0.58
NFE2L2 Q16236 2/20 0.58
HDAC3 O15379 1/20 0.58
HDAC4 P56524 1/20 0.58
HDAC1 Q13547 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
NCOR2 Q9Y618 1/20 0.58
MAPT P10636 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Phenethylcarbamate SCHEMBL6392045 0.95 LMNA (0.67) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL6554125 0.94 LMNA (0.65) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL13884390 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL10305302 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
Benzyl Phenethylcarbamate SCHEMBL27338403 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL8802503 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL9487307 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL160715 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL5511344 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL2851561 0.91 LMNA (0.61) LMNASMN1; SMN2HTTTGM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0754041-A4 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMA (US) 1997-11-19 EP claimed
EP-0754041-A1 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMACEUTICALS INCORPORATED (US) 1997-01-22 EP claimed
WO-1995026723-A1 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMACEUTICALS, INC. (US) 1995-10-12 WO claimed
CN-117800905-A Preparation method of 4- (2, 6-dimethyl-3-nitropyridin-4-ylamino) phenethyl carbamic acid benzyl ester 洛阳惠中兽药有限公司 2024-04-02 CN disclosed
CN-111164084-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-23 CN disclosed
US-11173480-B2 Catalyst in which metal is carried on inorganic porous body having hierarchical porous structure, and method for manufacturing said catalyst SNG INC. (JP) 2021-11-16 US disclosed
US-20200246779-A1 CATALYST IN WHICH METAL IS CARRIED ON INORGANIC POROUS BODY HAVING HIERARCHICAL POROUS STRUCTURE, AND METHOD FOR MANUFACTURING SAID CATALYST SNG INC. (JP) 2020-08-06 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2010-11-18 US disclosed
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US disclosed
US-20070167329-A1 Plant growth regulation BAYER CROPSCIENCE GMBH (DE) 2007-07-19 US disclosed
EP-1038874-A1 OXIME DERIVATIVES AND AGRICULTURAL CHEMICALS CONTAINING THE SAME DAINIPPON INK AND CHEMICALS, INC. (JP) 2000-09-27 EP disclosed
US-5807875-A OBESITY THERAPY DR. KARL THOMAE GMBH (DE) 1998-09-15 US disclosed
EP-0754041-A4 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMA (US) 1997-11-19 EP disclosed
EP-0754041-A1 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMACEUTICALS INCORPORATED (US) 1997-01-22 EP disclosed
US-5580878-A TREATING SLEEP DISORDERS INTERNEURON PHARMACEUTICALS, INC. (US) 1996-12-03 US disclosed
EP-0680488-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1995-11-08 EP disclosed
WO-1995026723-A1 NOVEL SUBSTITUTED TRYPTAMINES, PHENALKYLAMINES AND RELATED COMPOUNDS INTERNEURON PHARMACEUTICALS, INC. (US) 1995-10-12 WO disclosed
US-5403851-A Central nervous system and psychological disorders INTERNEURON PHARMACEUTICALS, INC. (US) 1995-04-04 US disclosed
WO-1994017090-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11173480-B2 Catalyst in which metal is carried on inorganic porous body having hierarchical porous structure, and method for manufacturing said catalyst TMEM63A, PORCN, PIEZO1 LMNA 4570/4885SMN1; SMN2 4029/4885HTT 3021/4885
US-20070167329-A1 Plant growth regulation TOE1, GHITM, GMDS LMNA 4839/4885SMN1; SMN2 4884/4885HTT 4857/4885
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC3, BIRC2 LMNA 605/4885SMN1; SMN2 3550/4885HTT 3072/4885
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS LMNA 1929/4885SMN1; SMN2 281/4885HTT 345/4885
US-20200246779-A1 CATALYST IN WHICH METAL IS CARRIED ON INORGANIC POROUS BODY HAVING HIERARCHICAL POROUS STRUCTURE, AND METHOD FOR MANUFACTURING SAID CATALYST TMEM63A, PORCN, PIEZO1 LMNA 4570/4885SMN1; SMN2 4029/4885HTT 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.